Scott C. Stromatt, M.D., MBA is our consulting physician at Skylark Biotherapeutics, where he provides medical input and management of our clinical programs. His career has spanned multiple clinical indications from Phase 1 to Phase 4, successful NDAs, and experience with various therapeutic modalities including small molecules, antibodies, bispecific antibodies, dendritic cell vaccines, antisense oligonucleotides, and AAV gene therapies. He has worked in multiple settings, including biotechnology, pharmaceutical, and contract research companies.

Previously, Dr. Stromatt was Senior Vice President, Chief Medical Officer, of Neurology Clinical Development at Ultragenyx, Chief Medical Officer at GeneTx Biotherapeutics, and Senior Vice President and Chief Medical Officer at Aptevo Therapeutics. Prior to that he was Chief Medical Officer at Emergent, Trubion, Cell Therapeutics and Northwest Biotherapeutics. He has worked developing dendritic cell vaccines, antibodies, and small molecules for hematologic and sold tumors. Additionally, he has worked on drugs in various rare diseases including: Angelman syndrome, cystic fibrosis, Lou Gehrig’s Disease, and acute myeloid leukemia.

He earned his MD from the University of Chicago Pritzker School of Medicine, and completed his residency at the University of New Mexico where he was a Chief Medical Resident. He is board certified in Internal Medicine and completed an MBA at the University of Colorado.